Although some studies have suggested that, unlike native insulin, the long-acting insulin analog glargine could be associated with a higher risk for cancer, especially breast cancer (241–246), re-analysis of these data, as well as further studies have found no differences in cancer risk for insulin glargine as compared with native insulin or other insulin analogs (240). Here, INS is linked to breast carcinoma.